Literature DB >> 16022955

Metabolic syndrome and risk of cardiovascular events after myocardial infarction.

Giacomo Levantesi1, Alejandro Macchia, RosaMaria Marfisi, Maria G Franzosi, Aldo P Maggioni, Gian L Nicolosi, Carlo Schweiger, Luigi Tavazzi, Gianni Tognoni, Franco Valagussa, Roberto Marchioli.   

Abstract

OBJECTIVES: We aimed to assess the prevalence and prognostic role of metabolic syndrome (METS) and diabetes in post-myocardial infarction (MI) patients.
BACKGROUND: Diabetes is a well known risk factor for patients with previous MI, but glycemic dysmetabolism develops over a protracted period of time. Scanty data are available on the role of METS in patients with previous MI.
METHODS: Adjusted Cox's regression models, having diabetes, death, major cardiovascular events (CVE), and hospitalization for congestive heart failure (CHF) during follow-up as outcome events, were fitted on 11,323 patients with prior MI enrolled in the GISSI-Prevenzione Trial.
RESULTS: At baseline, 21% and 29% of patients had diabetes mellitus and METS, respectively. The METS patients had a significant (93%) increased risk of diabetes during follow-up. As compared with control subjects, the probability of death and CVE were higher in both METS (+29%, p = 0.002; +23%, p = 0.005) and diabetic patients (+68%, p <0.0001; +47%, p <0.0001), although diabetic but not METS patients were more likely to be hospitalized for CHF (+89%, p <0.0003 and +24%, p = 0.241). Moderate (-6% to -10%) and substantial (>-10%) weight reduction were associated with a significant (18% and 41%, respectively) decreased risk of diabetes. Weight gain was significantly associated with increased risk of diabetes. The risk conferred by METS and diabetes tended to be higher among women.
CONCLUSIONS: In patients with MI, METS and diabetes were highly prevalent and are associated with increased risk of death and CVE. Diabetes is also associated with increased risk of hospitalization for CHF. Weight reduction significantly decreased the risk of becoming diabetic in patients with METS.

Entities:  

Mesh:

Year:  2005        PMID: 16022955     DOI: 10.1016/j.jacc.2005.03.062

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  38 in total

1.  APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome.

Authors:  Michael Miller; Jeffrey Rhyne; Hegang Chen; Valerie Beach; Richard Ericson; Kalpana Luthra; Manjari Dwivedi; Anoop Misra
Journal:  Arch Med Res       Date:  2007-03-26       Impact factor: 2.235

Review 2.  Optimizing management of metabolic syndrome to reduce risk: focus on life-style.

Authors:  Cristina Bianchi; Giuseppe Penno; Giuseppe Daniele; Luca Benzi; Stefano Del Prato; Roberto Miccoli
Journal:  Intern Emerg Med       Date:  2008-02-13       Impact factor: 3.397

3.  Metabolic syndrome predicts all-cause mortality in persons with human immunodeficiency virus.

Authors:  Olamide D Jarrett; Christine A Wanke; Robin Ruthazer; Ioana Bica; Rita Isaac; Tamsin A Knox
Journal:  AIDS Patient Care STDS       Date:  2013-05       Impact factor: 5.078

4.  Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial.

Authors:  Radmila Lyubarova; Jennifer G Robinson; Michael Miller; Debra L Simmons; Ping Xu; Beth L Abramson; Marshall B Elam; Todd M Brown; Ruth McBride; Jerome L Fleg; Patrice Desvigne-Nickens; Woubeshet Ayenew; William E Boden
Journal:  J Clin Lipidol       Date:  2017-07-05       Impact factor: 4.766

Review 5.  The treatment of obesity in cardiac rehabilitation.

Authors:  Philip A Ades; Patrick D Savage; Jean Harvey-Berino
Journal:  J Cardiopulm Rehabil Prev       Date:  2010 Sep-Oct       Impact factor: 2.081

6.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

7.  Insulin Resistance and Diabetes Mellitus in Contemporary Cardiac Rehabilitation.

Authors:  Sherrie Khadanga; Patrick D Savage; Philip A Ades
Journal:  J Cardiopulm Rehabil Prev       Date:  2016 Sep-Oct       Impact factor: 2.081

8.  Elevated risk of myocardial infarction in very young immigrants from former Yugoslavia.

Authors:  Franz Wiesbauer; Hermann Blessberger; Georg Goliasch; Erik Walter Holy; Stephan Pfaffenberger; Ioannis Tentzeris; Gerald Maurer; Kurt Huber; Farshid Abdolvahab; Gottfried Sodeck; Markus Exner; Johann Wojta; Martin Schillinger
Journal:  Eur J Epidemiol       Date:  2009-09-26       Impact factor: 8.082

9.  Impaired contractile recovery after low-flow myocardial ischemia in a porcine model of metabolic syndrome.

Authors:  Janice V Huang; Li Lu; Shuyu Ye; Bryan C Bergman; Genevieve C Sparagna; Mohammad Sarraf; Jane E B Reusch; Clifford R Greyson; Gregory G Schwartz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-01-18       Impact factor: 4.733

10.  Comparison of clinical outcomes following acute myocardial infarctions in hypertensive patients with or without diabetes.

Authors:  Min Goo Lee; Myung Ho Jeong; Youngkeun Ahn; Shung Chull Chae; Seung Ho Hur; Taek Jong Hong; Young Jo Kim; In Whan Seong; Jei Keon Chae; Jay Young Rhew; In Ho Chae; Myeong Chan Cho; Jang Ho Bae; Seung Woon Rha; Chong Jim Kim; Donghoon Choi; Yang Soo Jang; Junghan Yoon; Wook Sung Chung; Jeong Gwan Cho; Ki Bae Seung; Seung Jung Park
Journal:  Korean Circ J       Date:  2009-06-30       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.